CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 36.4% | 90.4% | 42.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 19.4% | -4.3% | -186% | -303.8% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 23.1% | -0.6% | -186.8% | -310.5% |
| EPS Diluted | 0.38 | -0.008 | -1.48 | -1.26 |
| % Growth | 5,035.1% | 99.5% | -17.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |